Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2919-2924

  Liu, Liang ^a   Chirala, Minni ^a   Younes, Mamoun ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Barrett's metaplasia; Esophagus cancer; Estrogen receptor beta

Indexed keywords

ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; ESTROGEN RECEPTOR BETA3; ESTROGEN RECEPTOR BETA5; ISOPROTEIN; PEROXIDASE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; BARRETT METAPLASIA; BARRETT METAPLASIA NEGATIVE FOR DYSPLASIA; CANCER INVASION; CLINICAL ARTICLE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METAPLASIA; PRECANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESTROGEN RECEPTOR BETA; HUMANS; IMMUNOHISTOCHEMISTRY; METAPLASIA; PROTEIN ISOFORMS;

EID: 6444230377     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Greene GL, Sobel NB, King WJ and Jensen EV: Immunochemical studies of estrogen receptors. J Steroid Biochem 20: 51-56, 1984.
2. Enmark E and Gustafsson JA: Oestrogen receptors - an overview. J Intern Med 246: 133-138, 1999.
3. Taylor AH and Al-Azzawi F: Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 24: 145-155, 2000.
4. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson JA and Hayashi SI: Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285: 340-347, 2001.
5. Torlakovic E, Lilleby W, Torlakovic G, Fossa SD and Chibbar R: Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum Pathol 33: 646-651, 2002.
6. Witte D, Chirala M, Younes A, Li Y and Younes M: Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol 32: 940-944, 2001.
7. Campbell-Thompson M, Lynch IJ and Bhardwaj B: Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 61: 632-640, 2001.
8. Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, Nakachi K, Gustafsson JA and Hayashi S: Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 128: 319-324, 2002.
9. Mann, S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y and Younes M: Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32: 113-118, 2001.
10. Shao ZM, Radziszewski WJ and Barsky SH: Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Lett 157: 133-144, 2000.
11. Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S and Iwase H: Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 163: 207-212, 2001.
12. Younes M, Henson DE, Ertan A and Miller CC: Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 37: 1359-1365, 2002.
13. Farrow DC and Vaughan TL: Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 7: 322-327, 1996.
14. Akgun H, Lechago J and Younes M: Estrogen receptor-beta is expressed in Barren's metaplasia and associated adenocarcinoma of the esophagus. Anticancer Res 22: 1459-1461, 2002.
15. Chi A, Chen X, Chirala M and Younes M: Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res 23: 211-216, 2003.
16. Blot WJ, Devesa SS, Kneller RW and Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 205: 1287-1289, 1991.
17. Blot WJ, Devesa SS and Fraumeni JF Jr: Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 270: 1320, 1993.
18. Yang PC and Davis S: Incidence of cancer of the esophagus in the US by histologic type. Cancer 61: 612-617, 1988.
19. Devesa SS, Blot WJ and Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83: 2049-2053, 1998.
20. Sampliner RE: Barren's esophagus, a complication of GERD. Curr Treat Options Gastroenterol 5: 45-50, 2002.
21. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ and Obertop H: Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43: 216-222, 1998.
22. Incarbone R, Bonavina L, Saino G, Bona D and Peracchia A: Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barren's esophagus. Surg Endosc 16: 263-266, 2002.
23. Ferguson MK and Durkin A: Long-term survival after esophagectomy for Barren's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg 6: 29-35; discussion 36, 2002.
24. Sampliner RE: Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 93: 1028-1032, 1998.
25. Sampliner RE: Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97: 1888-1895, 2002.
26. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC and Rabinovitch PS: Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 702: 1212-1219, 1992.
27. Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Zahurak ML and Hart J: Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32: 379-388, 2001.
28. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998.
29. Linsalata M, Messa C, Russo F, Cavallini A and Di Leo A: Estrogen receptors and polyamine levels in human gastric carcinoma. Scand J Gastroenterol 29: 67-70, 1994.
30. Wu CW, Tsay SH, Chang TJ, Chang HM, Hsieh MC, Lui WY, P' Eng FK and Chi CW: Clinicopathologic comparisons between estrogen receptor-positive and -negative gastric cancers. J Surg Oncol 51: 231-235, 1992.
31. Matsui M, Kojima O, Uehara Y and Takahashi T: Characterization of estrogen receptor in human gastric cancer. Cancer 65: 305-308, 1991.
32. Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P and Dietel M: Immunohistochemical differentiation of metastatic breast carcinomas from metastatic Sarawakadenocarcinomas of other common primary sites. Histopathology 29: 233-240, 1996.
33. Chaubert P, Bouzourene H and Saraga E: Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population. Mod Pathol 9: 189-193, 1996.
34. Sciascia C, Olivero G, Comandone A, Festa T, Fiori M G and Enrichens F: Estrogen receptors in colorectal adenocarcinomas and in other large bowel diseases. Int J Biol Markers 5: 38-42, 1990.
35. Waliszewski P, Blaszczyk M, Wolinska-Witort E, Drews M, Snochowski M and Hurst RE: Molecular study of sex steroid receptor gene expression in human colon and in colorectal carcinomas. J Surg Oncol 64: 3-11, 1997.
36. Ollayos CW, Riordan GP and Rushin JM: Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med 118: 630-632, 1994.
37. Brown RW, Campagna LB, Dunn JK and Cagle PT: Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 107: 12-19, 1997.
38. Ranelletti FO, Ricci R, Larocca LM, Maggiano N, Capelli A, Scambia G, Benedetti-Panici P, Mancuso S, Rumi C and Piantelli M. Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors. Int J Cancer 50, 486-492, 1992.
39. Xu X and Thomas ML: Estrogen receptor-mediated direct stimulation of colon cancer cell growth in vitro. Mol Cell Endocrinol 105: 197-201, 1994.
40. Di Domenico M, Castoria G, Bilancio A, Migliaccio A and Auricchio F: Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 56: 4516-4521, 1996.
41. Mosselman S, Polman J and Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996.
42. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F and Giguere V: Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 11: 353-365, 1997.
43. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M and Gustafsson JA: Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82: 4258-4265, 1997.
44. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y and Muramatsu M: The complete primary structure of human estrogen receptor beta (Her-Beta) and its heterodimerization with Er alpha in vivo and in vitro. Biochem Biophys Res Commun 243: 122-126, 1998.
45. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Home EL, Su JL, Kliewer SA, Lehmann JM and Willson TM: Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247: 75-78, 1998.
46. Fixemer T, Remberger K and Bonkhoff H: Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54: 79-87, 2003.
47. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S and Siegfried JM: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62: 2141-2150, 2002.
48. Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca G A, Bellastella A and Sinisi AA: Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 86: 2051-2055, 2001.
49. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA and Nilsson S: Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54: 105-112, 1998.
50. Cappelletti V, Veneroni S, Coradini D, Oriana S, Tomasic G, Younes M and Daidone MG: Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst 95: 629-630, 2003.
51. Lointier P, Wildrick DM and Boman BM: Growth effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa. Anticancer Res 12: 1523-1525, 1992.
52. Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Brand M and Fazio VW: The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro. Anticancer Res 14: 2005-2009, 1994.
53. Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Kitago K and Fazio VW: The effect of tamoxifen on established human colorectal cancer cell lines in vitro. Anticancer Res 16: 3767-3771, 1996.
54. Arai N, Strom A, Rafter JJ and Gustafsson JA: Estrogen receptor beta mRNA in colon cancer cells: growth effects of estrogen and genistein. Biochem Biophys Res Commun 270: 425-431, 2000.
55. Nakayama Y, Sakamoto H, Satoh K and Yamamoto T: Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 161: 63-71, 2000.